Travecta Therapeutics

Travecta Therapeutics is a biopharmaceutical company dedicated to developing a broad portfolio of candidates designed to cross the blood-brain barrier. The company's proprietary platform, mVECTATM, enables the screening and development of candidates that can cross the blood-brain barrier and target novel and untapped neurological pathways. Travecta Therapeutics was co-founded by Dr. David Silver, Dr. Mahmood Ahmed, and the SPRIM Ventures team.